Stock Watch: New Year, New Politics; Same Old Pricing And Generic Challenges

And Amarin Rallies Despite Unpromising Prospects

 
• By Andy Smith
  
Andy Smith
ANDY SMITH OFFERS A LIFE SCIENCE INVESTOR'S PERSPECTIVE ON BIOPHARMA BUSINESS

More from Drug Pricing

More from Scrip